peoplePerson
Robert D. Schreiber
Proposed cancer immunoediting and showed neoantigens are the targets of checkpoint immunotherapy.
Immunologist who established the three-phase immunoediting model and demonstrated that mutant neoantigens mediate rejection of checkpoint-treated tumours.
Role
Andrew M. and Jane M. Bursky Distinguished Professor; Director, Bursky Center for Human Immunology and Immunotherapy Programs
Institution
Specialisms
Cancer immunoeditingNeoantigensInterferon-gamma
Profiles
| Title | Journal | Year |
|---|---|---|
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Nature | 2014 |